Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2010 - 2026)

Jazz Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $74.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 10.04% year-over-year to $74.5 million in Q1 2026; TTM through Mar 2026 was $297.9 million, a 365.43% increase from a year earlier, with the FY2025 full-year figure at $291.1 million, up 404.1% from the prior year.
• Share-based Compensation advanced to $74.5 million in Q1 2026 per JAZZ's latest filing, from $70.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $150.9 million in Q3 2025 and bottomed at -$115.0 million in Q4 2022.
• The 5-year median for Share-based Compensation is $56.4 million (2023), against an average of $40.9 million.
• Across the five-year window, Share-based Compensation plunged 395.31% in 2022 and jumped 1669.14% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at -$115.0 million in 2022, then surged by 146.04% to $52.9 million in 2023, then tumbled by 92.43% to $4.0 million in 2024, then soared by 1669.14% to $70.9 million in 2025, then increased by 5.15% to $74.5 million in 2026.
• Per Business Quant, the three latest JAZZ Share-based Compensation figures stand at $74.5 million (Q1 2026), $70.9 million (Q4 2025), and $150.9 million (Q3 2025).